Juventas Cell Therapy, a China-based immunotherapy developer which counts pharmaceutical firm Casi Pharmaceuticals as a backer, has closed a $63m series C round, it has revealed.
The company had announced in July this year it has raised over $60m in a round co-led by Oceanpine Capital and China International Capital Corporation subsidiary CICC Capital that included Jiadao Private Capital, Redhill Capital, Delian Capital, Tianjin Venture Capital, Dalton Capital and Rfund.
Founded in 2018, Juventas is developing immuno-oncological treatments for blood diseases such as lymphoblastic leukaemia and haematologic tumours. Its lead drug candidate, CNCT19, targets blood diseases such as acute and chronic lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma.
Proceeds from the round will be used to seek a new drug application in China and support research and development and international commercialisation activities for CNCT19.
Commercial property developer Parkland Group’s Daxie Pengchuang Investment subsidiary backed a $68.4m round for the company in November 2020 led by CMG-SDIC Capital.
The November round also featured Kaixin Biotechnology, Tianjin Venture Capital, Ruisheng Investment, Tzitzit Asset, Xiangrong Capital, Dalton Venture and Jiadao Fanghua Investment.
Casi Pharmaceuticals led a $14.5m series A-plus round for Juventas in mid-2019, a month after it licenced the global rights to CNCT19, that included Dalton Venture and Panacea Venture. The company had secured $23.7m in series A funding from Redhill Capital and Dalton Venture the previous year.
